Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
about
Pancreatic cancer: New hopes after first line treatmentDocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma.Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting.Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial.Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer.Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma.A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancerUse of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinomaPancreatic adenocarcinomaCombination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).Overcoming drug resistance in pancreatic cancer.Long-time survival of a patient with metastatic pancreatic cancer: a case reportReduction of miR-29c enhances pancreatic cancer cell migration and stem cell-like phenotype.A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression.Adjuvant and neoadjuvant treatment in pancreatic cancerA 71-year-old man with a large cystic pancreatic mass.Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer.Pancreatic Cancer: Progress in Systemic Therapy.Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma.Neoadjuvant therapy in pancreatic cancer.Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials.The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer.Gemcitabine in the treatment of metastatic pancreatic cancer.A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancerHistamine regulation of pancreatitis and pancreatic cancer: a review of recent findings.Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?Gemox: a widely useful therapy against solid tumors-review and personal experience.Pancreatic cancer: current management and treatment strategies.Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure.Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature.Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.Pancreatic ductal adenocarcinoma: metastatic disease.Combined inhibition of PAK7, MAP3K7 and CK2alpha kinases inhibits the growth of MiaPaCa2 pancreatic cancer cell xenografts.NMDA receptors are important regulators of pancreatic cancer and are potential targets for treatment.Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer.S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure.Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancer.Capecitabine and oxaliplatin as first and second line treatment for locally advanced and metastatic pancreatic ductal adenocarcinoma.
P2860
Q28067055-6D9DDC01-69E8-441B-AAD1-848DC61B345DQ30315797-D1D4CE1D-DC7A-48D3-8B2F-3DC99DA08055Q33382236-18D7844D-92BB-46C7-83EC-073DC06F223DQ33394190-596E354D-45AF-4FE5-B1C4-35DAAE220C21Q33394729-B87DDDBA-3155-4213-8F28-EF13BF140E17Q33402401-5B54B500-54A9-456A-9D66-C45FC74F054AQ33415850-DC0F636A-B610-4C39-93D0-49661440CDECQ33428382-519DFFDD-CA18-48BD-8752-19F913655141Q33739625-FB43E31E-6623-4FF7-B58C-2E893A4B60F3Q33751227-EF382EB1-B1F4-4FF1-BBB3-44A1077CACD5Q34140498-016BCF81-D97A-4BEE-8D5A-7C0EC8389055Q34308370-8D4BD94C-7619-45C0-9746-ED09FB326547Q35036615-AF17321B-667E-414D-8162-BEB6040CC6F3Q35225648-36B36F23-64C8-4933-9ED1-0CDAD53E2806Q35550094-9ABB236F-1D23-4614-A1DC-EBD4688CA9BFQ35703105-4BC7C060-4F81-40B4-BA67-1C97AA677753Q35886631-96086448-CF6B-468F-B516-CB3FC1FECC4FQ35948154-788C8771-BC20-49C1-B349-761BDDAEE21DQ36219217-7957DA07-2255-4675-976B-097B77423DC0Q36344551-CE82C80E-40B5-49D1-8C0D-95D9741C078EQ36666645-BDC42A9F-B6F0-4183-BCA3-B22C95FA2FE1Q36871043-C1C53842-7766-4285-9744-F5C62DC06C6AQ37032865-DFD391B3-3E73-4460-B2BD-53615877F6D1Q37074126-A5AF81AF-8A25-4001-8464-2EF69485ABFEQ37134412-BFF65C34-4CB8-45D2-B4A0-2A5A2D539550Q37424087-7B64BC8E-A54F-4ED0-AD2B-5287E47FB9C5Q37584702-917226F5-A1EB-4B15-938D-9FF43E8FEB6BQ37617955-77D7FDB0-E70D-48CF-B89E-DAD316A6049EQ37814700-9B755226-EDDC-4C95-B248-6FC125F96011Q38561099-4BC3A7A4-C1EC-4ED8-9285-89DE88EFDA15Q38577917-AE22A548-62F2-4283-A36F-E5BB5EC2567AQ38736208-72B4B751-2E1C-43B2-AA56-49A2FDF70E02Q39140386-FB5437E2-B3CE-4ED0-AF87-C15F7301743FQ39379411-B5E4DBF4-0DA2-42C6-B337-C44603DFFBC1Q39861458-ECB36B06-648D-4386-9E89-53F07AB3C69DQ41096139-45E91D26-D85A-49DE-BD90-82551F211E00Q42681219-4DDD69B6-81AC-4867-B0CF-898E9E8F2F5BQ43147217-0087C960-79ED-4452-AEE0-05934F8C5DDDQ46581104-8F9C9207-D763-4D1D-A2B2-518B7E9EA403Q47143110-71E64C40-CD19-4565-A85B-61F9B7C39E1B
P2860
Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Gemcitabine and oxaliplatin (G ...... enocarcinoma: a phase II study
@ast
Gemcitabine and oxaliplatin (G ...... enocarcinoma: a phase II study
@en
Gemcitabine and oxaliplatin
@nl
type
label
Gemcitabine and oxaliplatin (G ...... enocarcinoma: a phase II study
@ast
Gemcitabine and oxaliplatin (G ...... enocarcinoma: a phase II study
@en
Gemcitabine and oxaliplatin
@nl
prefLabel
Gemcitabine and oxaliplatin (G ...... enocarcinoma: a phase II study
@ast
Gemcitabine and oxaliplatin (G ...... enocarcinoma: a phase II study
@en
Gemcitabine and oxaliplatin
@nl
P2093
P2860
P356
P1476
Gemcitabine and oxaliplatin (G ...... enocarcinoma: a phase II study
@en
P2093
A Hendlisz
E Monsaert
J L Van Laethem
R Marechal
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602966
P407
P577
2006-02-01T00:00:00Z
P5875
P6179
1023448352